FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311484532> ?p ?o ?g. }

• W4311484532 abstract "Loss of G2-specific E3-like (G2E3) protein sensitizes tumor cells to chemotherapy. However, the role of G2E3 in breast cancer development and patient's prognosis is unclear. Here, we explored the expression, prognostic significance, and regulatory pathway of G2E3 in breast cancer.TCGA and UALCAN database were utilized to explore G2E3 expression in breast cancer and normal tissues and its expression in breast cancer based on clinicopathological characteristics, respectively. The Kaplan-Meier plotter database was utilized to determine the effect of G2E3 on the prognosis of breast cancer patients. RT-PCR was utilized to validate the G2E3 expression in cancerous and normal breast tissues. Immunohistochemistry analysis was utilized to validate the prognostic effect of G2E3 expression in breast cancer patients and the relationship between G2E3 expression and lymphocyte infiltration levels. Receiver operating characteristic (ROC) curves were also generated to validate the diagnostic value of G2E3 expression in recurrence/distant organ metastasis and death. The STRING database, DAVID database, and Sanger-box tools were utilized to perform GO functional, KEGG pathway enrichment, and GSEA analysis. The TISIDB database was utilized to determine the relationship between G2E3 expression and tumor immunity. Finally, CTD database was utilized to screen for potential therapeutic compounds that could reduce the G2E3 mRNA expression.TCGA data presented that G2E3 expression was higher in breast cancer tissues than in normal breast tissues. This result was further validated by RT-PCR (P = 0.003). The Kaplan-Meier plotter database suggested that patients with high G2E3 mRNA expression had significantly shorter RFS and OS than patients with low G2E3 mRNA expression. Immunohistochemistry analysis of 156 breast cancer clinical specimens also validated patients with G2E3-positive expression had a significantly shorter DFS and OS than patients with G2E3-negative expression. Thus, G2E3 expression was an independent prognostic predictor of DFS and OS. The G2E3-positive expression also has a high diagnostic value for recurrence/distant organ metastasis and death. GSEA analysis revealed that G2E3 might be enriched in the E2F, PI3K/AKT/mTOR signaling, DNA repair pathways, and other cancer-related signaling pathways. The TISIDB database showed that G2E3 expression was significantly negatively associated with lymphocyte infiltration. This result was further validated in clinical breast cancer samples (P = 0.048; R = -0.158). Using the CTD database, we found that (+)-JQ1 compound, 1,2-dimethylhydrazine, and other compounds may decrease the G2E3 mRNA expression. These compounds could serve as potential therapeutic compounds for the clinical treatment of breast cancer.G2E3 expression was higher in breast cancer tissues than in normal tissues. G2E3-positive expression was related to a worse survival outcome in patients with breast cancer. Genes co-expressed with G2E3 may be enriched in the breast cancer-related signaling pathways. The G2E3 expression was significantly negatively associated with lymphocyte infiltration. G2E3 may serve as a novel prognostic biomarker and therapeutic target for breast cancer." @default.
• W4311484532 created "2022-12-26" @default.
• W4311484532 creator A5026107610 @default.
• W4311484532 creator A5028422293 @default.
• W4311484532 creator A5037566525 @default.
• W4311484532 creator A5055551987 @default.
• W4311484532 creator A5056692565 @default.
• W4311484532 creator A5060848619 @default.
• W4311484532 creator A5076498573 @default.
• W4311484532 creator A5080041548 @default.
• W4311484532 date "2022-12-15" @default.
• W4311484532 modified "2023-10-17" @default.
• W4311484532 title "Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer" @default.
• W4311484532 cites W1488814076 @default.
• W4311484532 cites W1853965828 @default.
• W4311484532 cites W1980827666 @default.
• W4311484532 cites W1994993231 @default.
• W4311484532 cites W2008978327 @default.
• W4311484532 cites W2018838463 @default.
• W4311484532 cites W2043398720 @default.
• W4311484532 cites W2055079033 @default.
• W4311484532 cites W2062889854 @default.
• W4311484532 cites W2090384315 @default.
• W4311484532 cites W2096173332 @default.
• W4311484532 cites W2099846133 @default.
• W4311484532 cites W2116760308 @default.
• W4311484532 cites W2130193848 @default.
• W4311484532 cites W2145200068 @default.
• W4311484532 cites W2151252396 @default.
• W4311484532 cites W2158217645 @default.
• W4311484532 cites W2207714175 @default.
• W4311484532 cites W2221588520 @default.
• W4311484532 cites W2346934180 @default.
• W4311484532 cites W2425463572 @default.
• W4311484532 cites W2560836545 @default.
• W4311484532 cites W2728365508 @default.
• W4311484532 cites W2736730167 @default.
• W4311484532 cites W2744067212 @default.
• W4311484532 cites W2782330970 @default.
• W4311484532 cites W2786427149 @default.
• W4311484532 cites W2805900947 @default.
• W4311484532 cites W2887894431 @default.
• W4311484532 cites W2890999095 @default.
• W4311484532 cites W2898309056 @default.
• W4311484532 cites W2932864461 @default.
• W4311484532 cites W2937441321 @default.
• W4311484532 cites W2944025126 @default.
• W4311484532 cites W2967901922 @default.
• W4311484532 cites W2988364315 @default.
• W4311484532 cites W3000376000 @default.
• W4311484532 cites W3004147826 @default.
• W4311484532 cites W3004398085 @default.
• W4311484532 cites W3008954267 @default.
• W4311484532 cites W3010197652 @default.
• W4311484532 cites W3014160477 @default.
• W4311484532 cites W3037368215 @default.
• W4311484532 cites W3044931952 @default.
• W4311484532 cites W3082090251 @default.
• W4311484532 cites W3092539994 @default.
• W4311484532 cites W3093194543 @default.
• W4311484532 cites W3118345283 @default.
• W4311484532 cites W3128646645 @default.
• W4311484532 cites W3185354749 @default.
• W4311484532 doi "https://doi.org/10.1186/s12957-022-02871-0" @default.
• W4311484532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36517818" @default.
• W4311484532 hasPublicationYear "2022" @default.
• W4311484532 type Work @default.
• W4311484532 citedByCount "0" @default.
• W4311484532 crossrefType "journal-article" @default.
• W4311484532 hasAuthorship W4311484532A5026107610 @default.
• W4311484532 hasAuthorship W4311484532A5028422293 @default.
• W4311484532 hasAuthorship W4311484532A5037566525 @default.
• W4311484532 hasAuthorship W4311484532A5055551987 @default.
• W4311484532 hasAuthorship W4311484532A5056692565 @default.
• W4311484532 hasAuthorship W4311484532A5060848619 @default.
• W4311484532 hasAuthorship W4311484532A5076498573 @default.
• W4311484532 hasAuthorship W4311484532A5080041548 @default.
• W4311484532 hasBestOaLocation W43114845321 @default.
• W4311484532 hasConcept C104317684 @default.
• W4311484532 hasConcept C10515644 @default.
• W4311484532 hasConcept C121608353 @default.
• W4311484532 hasConcept C126322002 @default.
• W4311484532 hasConcept C143998085 @default.
• W4311484532 hasConcept C150194340 @default.
• W4311484532 hasConcept C152724338 @default.
• W4311484532 hasConcept C162317418 @default.
• W4311484532 hasConcept C204232928 @default.
• W4311484532 hasConcept C2780140570 @default.
• W4311484532 hasConcept C41008148 @default.
• W4311484532 hasConcept C502942594 @default.
• W4311484532 hasConcept C530470458 @default.
• W4311484532 hasConcept C55493867 @default.
• W4311484532 hasConcept C71924100 @default.
• W4311484532 hasConcept C77088390 @default.
• W4311484532 hasConcept C86803240 @default.
• W4311484532 hasConceptScore W4311484532C104317684 @default.
• W4311484532 hasConceptScore W4311484532C10515644 @default.
• W4311484532 hasConceptScore W4311484532C121608353 @default.
• W4311484532 hasConceptScore W4311484532C126322002 @default.
• W4311484532 hasConceptScore W4311484532C143998085 @default.

• next